The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease

Sandra J. Bliss, Katherine L. O'Brien, Edward N. Janoff, Mark F. Cotton, Philippa Musoke, Hoosen Coovadia, Orin S. Levine

Research output: Contribution to journalReview article

Abstract

Pneumococcal conjugate vaccines (PCVs) are a potentially useful complement to existing treatment strategies in HIV-infected children, for whom pneumococcal infections are common and serious. This Review summarises available data on the burden of pneumococcal disease and the safety and efficacy of PCVs in HIV-infected children. The data demonstrate that children with HIV have significantly increased risk of pneumococcal disease compared with uninfected children; the serotypes included in currently licensed or near-licensure conjugate vaccines include most serotypes that cause invasive pneumococcal disease (IPD) in HIV-infected children and adults; PCVs provide substantial protection against IPD and clinical pneumonia when given to HIV-infected infants; and HIV-infected adults gain an indirect benefit when children in the community are vaccinated. PCV should be considered as an important intervention for improving the lives of HIV-infected children.

Original languageEnglish (US)
Pages (from-to)67-80
Number of pages14
JournalThe Lancet Infectious Diseases
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease'. Together they form a unique fingerprint.

  • Cite this